Niedziela Natalia, Adamczyk-Sowa Monika, Niedziela Jacek T, Mazur Bogdan, Kluczewska Ewa, Sowa Paweł, Gąsior Mariusz
Department of Neurology in Zabrze, Medical University of Silesia, ul. 3-go Maja 13-15, 41-800 Zabrze, Poland.
3rd Department of Cardiology, SMDZ in Zabrze, Medical University of Silesia, Silesian Centre for Heart Disease, ul. Curie-Skłodowskiej 9, 41-800 Zabrze, Poland.
Biomed Res Int. 2016;2016:4570351. doi: 10.1155/2016/4570351. Epub 2016 Dec 19.
The role of nitric oxide and its reactive derivatives (NO ) is well known in the pathogenesis of multiple sclerosis, which is an inflammatory disease while NO seems to be important in coordinating inflammatory response. The purpose of the present study was to assess serum NO as one of the nitrogen species and inflammatory parameters in relapsing-remitting multiple sclerosis patients and to compare the effectiveness of various types of disease-modifying therapies that reduce nitric oxide and inflammatory biomarkers. Elevated NO level was observed in patients who received the first-line disease-modifying therapy (interferons beta-1a and beta-1b) in comparison with the subjects treated with the second-line disease-modifying therapy (natalizumab; fingolimod) and healthy controls without significant differences in C-reactive protein and interleukin-1 beta. A negative correlation was observed between serum NO level and the duration of multiple sclerosis confirmed in the whole study population and in subjects treated with the first-line agents. Only serum NO , concentration could reveal a potential efficacy of disease-modifying therapy with a better reduction in NO level due to the second-line agents of disease-modifying therapy.
一氧化氮及其反应性衍生物（NO ）在多发性硬化症发病机制中的作用已广为人知，多发性硬化症是一种炎症性疾病，而NO 在协调炎症反应中似乎很重要。本研究的目的是评估血清NO 作为复发缓解型多发性硬化症患者的含氮物质和炎症参数之一，并比较各种降低一氧化氮和炎症生物标志物的疾病修饰疗法的有效性。与接受二线疾病修饰疗法（那他珠单抗；芬戈莫德）的受试者和健康对照相比，接受一线疾病修饰疗法（干扰素β-1a和β-1b）的患者中观察到NO 水平升高，C反应蛋白和白细胞介素-1β无显著差异。在整个研究人群以及接受一线药物治疗的受试者中，观察到血清NO 水平与多发性硬化症病程之间呈负相关。只有血清NO 浓度可以揭示疾病修饰疗法的潜在疗效，由于二线疾病修饰疗法药物，NO 水平降低得更好。
